Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target

Benzinga Newsdesk www.benzinga.com Negative 57.0%

Neg 57% Neu 0% Pos 0%

Stephens & Co. analyst Sudan Loganathan reiterates Actinium Pharma (AMEX:ATNM) with a Overweight and maintains $5 price target.